A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

Bruton’s tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK‐020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling. We assessed the safety/tolerability and pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales: Esfandiari, Ehsanollah, Chen, Mary, Smithson, Glennda, Blair, Derek, Faessel, Helene, Wagner, John, Mclean, Lachy, Fedyk, Eric R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212709/
https://www.ncbi.nlm.nih.gov/pubmed/33650758
http://dx.doi.org/10.1111/cts.12871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212709/
https://www.ncbi.nlm.nih.gov/pubmed/33650758
http://dx.doi.org/10.1111/cts.12871

Ejemplares similares